Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.
High Blood Press Cardiovasc Prev. 2023 Jan;30(1):37-44. doi: 10.1007/s40292-022-00554-1. Epub 2022 Nov 30.
Elabela is a newly identified peptide which, alongside apelin, acts as an endogenous ligand that activates the angiotensin receptor-like 1 receptor. Previous studies have shown the association of elabela with hypertension, but information about the role of elabela in hypertension-related subclinical atherosclerosis is scarce.
We aimed to determine the elabela levels in hypertensive patients and explore its association with subclinical atherosclerosis.
A total of 104 subjects with hypertension were included in the study. Elabela levels were measured using an enzyme-linked immunosorbent assay, by first extracting the peptide following the manufacturer's instructions. Subclinical atherosclerosis was assessed by measuring the carotid intima-media thickness (IMT) using ultrasound.
Compared to stage 1, elabela levels decreased in stage 2 hypertension (0.23 [0.13, 0.45] ng/ml vs. 0.14 [0.09, 0.23] ng/ml; P = 0.000), and in the group with increased carotid IMT compared to normal IMT (0.24 [0.13, 0.38] ng/ml vs. 0.15 [0.10, 0.23] ng/ml; P = 0.005). Additionally, a linear correlation analysis showed that elabela had a significant negative correlation with systolic blood pressure (r = - 0.340, P = 0.000) and carotid IMT (r = - 0.213; P = 0.030). In multivariate analysis, lower elabela levels were associated with a higher cardiovascular risk group in this study (OR 5.0, 95% CI 1.8-13.5, P < 0.001).
This study demonstrated for the first time that circulating elabela declined in a higher stage of hypertension and hypertensive patients with increased carotid IMT, implicating that elabela may be involved in the pathogenesis of hypertension-associated subclinical atherosclerosis.
Elabela 是一种新发现的肽类物质，与 apelin 一起作为内源性配体激活血管紧张素受体样 1 受体。先前的研究表明 Elabela 与高血压有关，但关于 Elabela 在与高血压相关的亚临床动脉粥样硬化中的作用的信息很少。
我们旨在确定高血压患者的 Elabela 水平，并探讨其与亚临床动脉粥样硬化的关系。
本研究共纳入 104 例高血压患者。首先按照说明书提取肽，然后使用酶联免疫吸附试验测定 Elabela 水平。使用超声测量颈动脉内膜-中层厚度（IMT）来评估亚临床动脉粥样硬化。
与 1 期相比，2 期高血压患者的 Elabela 水平降低（0.23[0.13，0.45]ng/ml 比 0.14[0.09，0.23]ng/ml；P=0.000），颈动脉 IMT 增加的患者与颈动脉 IMT 正常的患者相比，Elabela 水平降低（0.24[0.13，0.38]ng/ml 比 0.15[0.10，0.23]ng/ml；P=0.005）。此外，线性相关分析显示 Elabela 与收缩压（r=-0.340，P=0.000）和颈动脉 IMT（r=-0.213；P=0.030）呈显著负相关。在多变量分析中，较低的 Elabela 水平与该研究中更高的心血管风险组相关（OR 5.0，95%CI 1.8-13.5，P<0.001）。
本研究首次表明，循环 Elabela 在更高阶段的高血压和颈动脉 IMT 增加的高血压患者中下降，提示 Elabela 可能参与高血压相关亚临床动脉粥样硬化的发病机制。
